No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset

E J A Kroot, M A van Leeuwen, M H van Rijswijk, M L L Prevoo, M A Van ’t Hof, L B A van de Putte, P L C M van Riel

Abstract

Objective—To investigate mortality, functional capacity, and prognostic factors for mortality in an inception cohort of patients with recently diagnosed RA followed up for up to 10 years.

Methods—The observed mortality of this inception cohort with recently diagnosed RA, was analysed in relation to the expected mortality, calculated with the aid of life tables of the general population of the Netherlands (matched for age and sex). Functional capacity was measured by the Health Assessment Questionnaire. Prognostic factors for mortality were analysed multivariately by the Cox proportional hazards model.

Results—Between January 1985 and April 1997, 622 patients entered the study, and were included in the analysis of mortality. The death rate in the first 10 years of the disease was not significantly different from that of the general population. Fifty five patients from the study group died (16% up to 10 years of follow up). The most commonly reported causes of death were cardiovascular and respiratory origin. The other causes of death could be classified into cancer, sepsis, amyloidosis, leukaemia, renal insufficiency of unknown cause, perforation of the oesophagus, probably related to the treatment with non-steroidal anti-inflammatory drugs, and pancytopenia during aurothioglucose treatment. Functional capacity improved significantly during the first six years compared with the value at start. Statistically significant predictors for death were age at the start and male sex.

Conclusions—In contrast with earlier studies performed, no excess mortality in the first 10 years of an inception cohort of patients with recent onset RA (symptoms for less than one year at study entry). Two studies concerned patients already included before 1975, and in both studies an increased death rate was found. In contrast, in a recently published inception cohort study no increased death rate was found, but progressive functional impairment during the first years of the disease was seen in these patients.

In the past decade there has been a dramatic change in the pharmacotherapy: the number of available non-steroidal anti-inflammatory drugs (NSAIDs) has increased, but probably more importantly sulfasalazine and methotrexate, the two most commonly used disease modifying antirheumatic drugs (DMARDs) at present, were introduced in the treatment of RA. In addition, DMARDs are given earlier in the disease course, sometimes even in combinations. It has been assumed that this more aggressive treatment strategy has influenced the disease course beneficially at the long term, though this has not yet been proved.

In several studies increased death rates have been reported for infections, especially respiratory infections, gastrointestinal related deaths, and lymphoproliferative diseases. The prevalence of cardiovascular deaths and deaths from carcinomas in patients with RA has been reported to be roughly the same as in the general population.

We evaluated the causes of death in this present study.

In most studies the possibility of predicting mortality has also been investigated. A great variety of prognostic factors have been reported so far: age, sex, formal educational level, rheumatoid factor (RF), the presence of rheumatoid nodules at the first visit, joint count, activities of daily living, oral corticosteroid use, erythrocyte sedimentation rate (ESR), disease duration, and extra-articular manifestations of RA, particularly vasculitis. Because no consistency exists in the design of these studies, it is still unclear which variables are predictive for mortality.

In this study, which was started in 1985, the death rate, causes of death, functional disability, and possible prognostic factors for mortality were investigated in an inception cohort of
The functional capacity of patients attending the Nijmegen University Hospital (n=322), for whom Health Assessment Questionnaires were available at each year of follow up (n=249), are presented for each year of the follow up (table 2).

Prognostic factors for mortality were analysed multivariately by the Cox proportional hazards model, multivariate with age (start of RA), sex (male or female), IgM rheumatoid factor (IgM RF positive or negative), HLA status, RA, number of swollen joints (range 0–44), mean DAS of first year of follow up (range 0–10), and ESR fixed in the model. All variables were continuous, except sex, IgM RF, and HLA status. Patients for whom all baseline characteristics were available were included in the model (n=566). The dependent variable in the model was duration of follow up. In a separate analysis the mean HAQ of the first year was included in the Cox proportional hazards model as well.

Results

MORTALITY AND FUNCTIONAL CAPACITY

By April 1997 622 patients had entered the study and were included in the various analyses. Table 1 presents the baseline characteristics of the clinical variables of the study group. Figure 1 shows the number of patients at each time point during 10 years of follow up. Mean duration of follow up was 5.8 years (range 1–10), and 109 patients were followed up for 10 years. Of the total study group of 622 patients with recently diagnosed RA, 55 patients (16% of the patients up to 10 years of follow up) died during the period of observation with a mean age at death of 73 years. The patients included had a similar prevalence of chronic comorbidities as patients with other chronic diseases, also having other comorbidities, living in the same area as the patients with RA. The life/death status could not be traced in two of the 35 patients who were lost to follow up at April 1997.

The causes of death ascribed by the rheumatologists or general practitioners could be classified as cardiovascular (n=26) and respiratory cause (n=6), cancer (n=17), sepsis (n=1), amyloidosis (n=2), renal insufficiency of unknown cause (n=1), perforation of the oesophagus, probably related to NSAID treatment (n=1), and pancytopenia during aurothioglucone treatment (n=1).

Table 1  Baseline characteristics of the study group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients (n=622)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>386 (62)</td>
</tr>
<tr>
<td>Age at study start (years)</td>
<td>53.3 (18–86)</td>
</tr>
<tr>
<td>IgM RF+ (&gt;10 IU)</td>
<td>510 (82)</td>
</tr>
<tr>
<td>HLA-DR4+</td>
<td>336 (54)</td>
</tr>
<tr>
<td>ESR† (mm/1st hour)</td>
<td>40.7 (2.0–135.0)</td>
</tr>
<tr>
<td>Disease activity score</td>
<td>4.0 (2.8–5.6)</td>
</tr>
<tr>
<td>Ritchie Articular Index</td>
<td>12.3 (3.9–27.0)</td>
</tr>
<tr>
<td>Health Assessment Questionnaire</td>
<td>0.67 (0–1.97)</td>
</tr>
<tr>
<td>DMARD† (first year)</td>
<td>566 (91)</td>
</tr>
<tr>
<td>DMARD (follow up)</td>
<td>591 (95)</td>
</tr>
<tr>
<td>Corticosteroids (first year)</td>
<td>124 (20)</td>
</tr>
<tr>
<td>Corticosteroids (follow up)</td>
<td>212 (34)</td>
</tr>
</tbody>
</table>

*Mean values (range) and numbers (percentages) are given.
†ESR = erythrocyte sedimentation rate; DMARD = disease modifying antirheumatic drug.

The life/death status could not be traced in two of the 35 patients who were lost to follow up at April 1997.

The causes of death ascribed by the rheumatologists or general practitioners could be classified as cardiovascular (n=26) and respiratory cause (n=6), cancer (n=17), sepsis (n=1), amyloidosis (n=2), renal insufficiency of unknown cause (n=1), perforation of the oesophagus, probably related to NSAID treatment (n=1), and pancytopenia during aurothioglucone treatment (n=1).
Figure 2 presents survival functions (Kaplan-Meier) of the patients with RA (n=622) compared with the general population of the Netherlands, matched for age and sex. Confidence intervals (95%) are shown for the study group compared with the general population of the Netherlands, matched for age and sex.

PROGNOSTIC FACTORS

Patients for whom all baseline characteristics were available were included in the model (n=566). Table 3 presents the results. Age at the start (p=0.0001) and male sex (p=0.02) were the only significant prognostic factors for death. IgM RF, though not statistically significant, appeared to have some prognostic power (p=0.06). The level of education proved to be lower in the RA cohort than in the Dutch working or the Dutch general population, but after adjustment for age and sex the difference disappeared. None of the other variables was a statistically significant prognostic factor.

Table 3: Results of multivariate Cox regression analyses of the prognostic values of selected variables at study entry in patients with rheumatoid arthritis

<table>
<thead>
<tr>
<th>Variables</th>
<th>Risk ratio (conditional)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male sex)</td>
<td>0.56</td>
<td>0.02</td>
</tr>
<tr>
<td>Age (at study start)</td>
<td>1.12</td>
<td>0.0001</td>
</tr>
<tr>
<td>IgM RF</td>
<td>2.51</td>
<td>0.06</td>
</tr>
<tr>
<td>HLA-DR4+</td>
<td>0.85</td>
<td>0.57</td>
</tr>
<tr>
<td>ESR*</td>
<td>0.99</td>
<td>0.18</td>
</tr>
<tr>
<td>Disease Activity Score</td>
<td>2.69</td>
<td>0.12</td>
</tr>
<tr>
<td>Ritchie Articular Index</td>
<td>0.95</td>
<td>0.29</td>
</tr>
<tr>
<td>Total swollen joints</td>
<td>0.94</td>
<td>0.21</td>
</tr>
</tbody>
</table>

*ESR = erythrocyte sedimentation rate

Discussion

In this prospective study, started in 1985, the death rate of an inception cohort of patients with recent onset RA was analysed. Fifty-five patients of the study group of 622 patients died during the period of observation. The observed mortality of this study group up to 10 years of follow up was comparable with the expected mortality, calculated with the aid of life tables, of the general population of the Netherlands (matched for age and sex). This finding is in contrast with the general belief that RA is associated with an increased death rate.

Only three studies report the mortality in patients followed up prospectively from onset. In the study of Corbett et al a small increase in mortality, compared with population expected rates, was found (these data were not analysed statistically). This excess mortality increased with increasing duration of disease, but was already apparent after three years of follow up. The study of Rasker and Cosh, also including an inception cohort of patients with RA who satisfied the ARA criteria of definite or classical RA within one year of onset, did not compare their results with the general population (that is, the population of the UK). However, an increase in mortality, between the third and tenth year after baseline, with a loss of life expectancy of at least five years was suggested. A striking difference between the study of Rasker and Cosh and our data is the mean age at death (73 years in this study v 68 years in the study of Rasker et al). In contrast, only the study of Lindquist and Eberhardt found no increased mortality.

The causes of death observed in our study were comparable with the results seen in the three inception cohort studies, except for two deaths related to treatment which occurred in this study. In the three previous studies second line drugs were not responsible for any
deaths, probably owing to the relatively small numbers of patients in those studies. In the study of Lindquist and Eberhard only 62% of the patients were treated with DMARDs and 16% with oral corticosteroids at some time during follow up. In our study 91% of the patients were already being treated with DMARDs during the first year of follow up and 95% of the patients were treated with DMARDs at some time during follow up. In addition, 20% of the patients used oral corticosteroids at some time during the first year of observation, and 35% of the patients used oral corticosteroids at some time during the complete follow up period. In the Netherlands there is a general policy of referring patients with RA early in the disease course to a rheumatologist. Therefore none of the patients had started taking DMARDs or corticosteroids before inclusion in the study. Although it seems logical to suggest that the early use of second line treatment might lead to treatment related mortality, this was not confirmed by our study as no increased mortality was found. In other mortality studies increased death rates in patients with RA were reported as a result of infection, especially respiratory infection, gastrointestinal and lymphoproliferative diseases. However, most of these studies had different definitions of RA, disease duration before study inclusion, and length of follow up, and most patients received steroid treatment for several years. The functional capacity was relatively constant during the first six years after an initial improvement from baseline. After 10 years of follow up the functional capacity had returned to the level at the start of the study. This is in contrast with the study of Corbett et al, in which disability was reported to develop most rapidly during the first year after disease onset, with a slow, nearly linear rate of increase during the period of observation. In the study of Eberhardt and Fex, in which no increased mortality was found in an inception cohort of patients with RA, it was concluded that functional impairment of different joints had progressed, but most patients were mildly disabled up to six years of follow up. In that study fewer patients were treated with second line drugs or corticosteroids during follow up, and therefore we suggest that the early use of second line treatment in our study, in almost all patients, might have led to improved functional capacity but not to increased mortality.

Different variables at onset were also analysed for their prognostic value for mortality. No univariate analysis was performed, as mortality and several disease activity variables are highly age and sex related. Therefore age would act as a confounder in a univariate analysis. In the regression model only age at start and male sex were statistically significant prognostic factors. The results are in line with the results of the study of Lindquist and Eberhard. This is unsurprising, as age and sex are the strongest predictors of mortality in the general population as well. However, Anderson, who reviewed 25 articles on age and mortality in RA, failed to show a clear association between sex, age, and mortality in RA. Corbett et al and Rasker and Cosk did not analyse prognostic factors for mortality. Corbett et al showed that, compared with survivors, patients who had severe disease, were more often treated with steroids, and became more disabled during the course of their illness. Rasker and Cosk suggested a longer life expectancy for women, a greater chance of early death for patients with a bad functional status and for patients with persistently high ESR and with strong seropositivity for RF. However, these suggestions were not analysed statistically.

It has long been suggested that patients with RA, especially the more severe cases, have a shorter life expectancy compared to the general population. In this study of an inception cohort of patients with recent onset RA we conclude that the death rate up to 10 years of follow up of patients with RA was not significantly different from the expected mortality of the general population. Therefore we suggest that the aggressive therapeutic strategies introduced since the 1980s have not only resulted in an improved disease course but also in a better long term outcome. But we are aware that other possibilities cannot be excluded—for example, some evidence suggested that patients gaining weight and becoming common and the fact that patients attending hospitals are more likely to receive preventive treatment for comorbidities. However, some studies have suggested that the mortality of patients with RA compared with the general population increases with the duration of the disease, further research (longer follow up) may be necessary. In this study only age at the start and male sex were statistically significant prognostic factors for mortality.

We are grateful to all patients for completing the various assessments. We thank our rheumatology research nurses, D van den Akker, A ter Avest, J Deenen, and L Theunisse, for their assistance in data collection. This study was supported by a grant from “Het Nationaal Reumafonds” of the Netherlands (The Dutch League against Rheumatism).

5 Gabriel SE, Crowson CS, O’Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529–33.


